Foghorn Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Foghorn Therapeutics
FHTX Stock  USD 7.72  0.14  1.78%   
Foghorn Therapeutics financial statements provide useful quarterly and yearly information to potential Foghorn Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Foghorn Therapeutics financial statements helps investors assess Foghorn Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Foghorn Therapeutics' valuation are summarized below:
Gross Profit
-86.4 M
Market Capitalization
437 M
Enterprise Value Revenue
8.177
Revenue
25.5 M
Earnings Share
(1.85)
We have found one hundred twenty available fundamental signals for Foghorn Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Foghorn Therapeutics prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 257.2 M in 2024. Enterprise Value is likely to drop to about 223.7 M in 2024

Foghorn Therapeutics Total Revenue

35.86 Million

Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 11.1 M, Interest Income of 11.1 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 7.53, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Foghorn Therapeutics Correlation against competitors.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Foghorn Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets280.8 M285.9 M143.8 M
Slightly volatile
Short and Long Term Debt Total47.8 M45.1 M24.3 M
Slightly volatile
Total Current Liabilities87.8 M58.4 M39.6 M
Slightly volatile
Other Liabilities176 M349.6 M78.8 M
Slightly volatile
Property Plant And Equipment Net39.7 M42.9 M18.2 M
Slightly volatile
Accounts Payable4.5 M6.3 M3 M
Slightly volatile
Cash123.8 M80.3 M74.6 M
Slightly volatile
Non Current Assets Total43.6 M45.7 M20.2 M
Slightly volatile
Non Currrent Assets Other2.7 M2.8 M1.5 M
Slightly volatile
Other Assets0.951.01.2 M
Slightly volatile
Long Term Debt13.8 M22.6 M11.3 M
Slightly volatile
Cash And Short Term Investments178.7 M234.1 M98.3 M
Slightly volatile
Common Stock Shares Outstanding39.2 M42 M27.3 M
Slightly volatile
Liabilities And Stockholders Equity280.8 M285.9 M143.8 M
Slightly volatile
Non Current Liabilities Total185.9 M304.7 M122.1 M
Slightly volatile
Other Current Assets5.2 M6.1 M2.5 M
Slightly volatile
Other Stockholder Equity266.4 M395.2 M117 M
Slightly volatile
Total Liabilities273.7 M363.1 M161.7 M
Slightly volatile
Property Plant And Equipment Gross36.6 M54.9 M16.9 M
Slightly volatile
Total Current Assets237.1 M240.2 M123.6 M
Slightly volatile
Net Working Capital202 M181.7 M106.6 M
Slightly volatile
Common Stock3.3 K4.6 K2 K
Slightly volatile
Property Plant Equipment38.2 M56.8 M19 M
Slightly volatile
Current Deferred Revenue32.8 M34.5 M31.1 M
Slightly volatile
Short and Long Term Debt3.3 M3.7 M4.1 M
Slightly volatile
Short Term Debt12.4 M17 M7.9 M
Slightly volatile
Net Receivables2.6 M2.7 M21.1 M
Pretty Stable
Common Stock Total Equity3.2 K3.6 K3.9 K
Slightly volatile
Short Term Investments163.2 M153.7 M112.4 M
Slightly volatile
Capital Surpluse384.1 M433.8 M330.4 M
Slightly volatile
Non Current Liabilities Other24.8 K26.1 K119.7 K
Slightly volatile

Foghorn Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income11.1 M10.6 M2.2 M
Slightly volatile
Depreciation And Amortization3.9 M3.5 M1.9 M
Slightly volatile
Interest Expense14 M13.3 M3 M
Slightly volatile
Selling General Administrative19.7 M32.4 M11.1 M
Slightly volatile
Other Operating Expenses96.5 M142.1 M55.4 M
Slightly volatile
Research Development76.8 M109.7 M44.4 M
Slightly volatile
Total Operating Expenses96.5 M142.1 M55.4 M
Slightly volatile
Reconciled Depreciation2.3 M3.4 M1.2 M
Slightly volatile
Cost Of Revenue115.2 M109.7 M20.5 M
Slightly volatile
Non Operating Income Net Other10 M9.5 M2.5 M
Slightly volatile
Selling And Marketing Expenses4.2 M4.7 M5.1 M
Slightly volatile

Foghorn Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.1 M16.2 M3.9 M
Slightly volatile
Begin Period Cash Flow59.1 M53.9 M32.4 M
Slightly volatile
Other Cashflows From Financing Activities1.7 M1.8 M39.1 M
Slightly volatile
Depreciation2.3 M3.5 M1.2 M
Slightly volatile
Other Non Cash Items3 M2.6 M1.3 M
Slightly volatile
Capital Expenditures1.2 M1.2 M2.5 M
Pretty Stable
Total Cash From Financing Activities1.7 M1.8 M49 M
Pretty Stable
End Period Cash Flow71.7 M82 M52.5 M
Slightly volatile
Change To Netincome17.3 M16.5 M5.1 M
Slightly volatile
Change To Liabilities5.1 M3.5 M2.8 M
Slightly volatile
Sale Purchase Of Stock1.5 M1.6 M93.7 M
Slightly volatile
Cash Flows Other Operating341.8 M325.5 M87.1 M
Slightly volatile
Other Cashflows From Investing Activities200 K225 K245 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.537.92671.3 K
Slightly volatile
Days Sales Outstanding66.4 K74.7 K81.4 K
Slightly volatile
Average Payables2.2 M2.5 M2.7 M
Slightly volatile
Stock Based Compensation To Revenue0.450.47395.5848
Slightly volatile
Capex To Depreciation0.340.35473.4848
Slightly volatile
Payables Turnover18.417.52223.7195
Slightly volatile
Sales General And Administrative To Revenue0.90.947820.5072
Slightly volatile
Research And Ddevelopement To Revenue3.053.2115103
Slightly volatile
Capex To Revenue0.0340.035827.7752
Slightly volatile
Cash Per Share4.345.57623.5496
Slightly volatile
Days Payables Outstanding19.7920.83078.1 K
Pretty Stable
Current Ratio6.914.11029.204
Slightly volatile
Receivables Turnover0.00350.0040.0043
Slightly volatile
Graham Number9.639.85018.2862
Pretty Stable
Capex Per Share0.02770.02920.0899
Very volatile
Revenue Per Share0.850.81370.1527
Slightly volatile
Interest Debt Per Share0.190.20290.5076
Very volatile
Debt To Assets0.02830.02980.4132
Very volatile
Operating Cycle66.4 K74.7 K81.4 K
Slightly volatile
Days Of Payables Outstanding19.7920.83078.1 K
Pretty Stable
Ebt Per Ebit1.070.8730.9988
Slightly volatile
Quick Ratio6.914.11029.204
Slightly volatile
Net Income Per E B T0.821.04491.0002
Slightly volatile
Cash Ratio1.311.37487.7348
Slightly volatile
Days Of Sales Outstanding66.4 K74.7 K81.4 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.221.01041.096
Pretty Stable
Fixed Asset Turnover0.840.79590.1416
Slightly volatile
Debt Ratio0.02830.02980.4132
Very volatile
Price Sales Ratio7.537.92671.3 K
Slightly volatile
Asset Turnover0.130.11950.0212
Slightly volatile

Foghorn Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap257.2 M270.7 M417.2 M
Pretty Stable

Foghorn Fundamental Market Drivers

Cash And Short Term Investments234.1 M

Foghorn Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue34.5 M32.8 M
Total Revenue34.2 M35.9 M
Cost Of Revenue109.7 M115.2 M
Stock Based Compensation To Revenue 0.47  0.45 
Sales General And Administrative To Revenue 0.95  0.90 
Research And Ddevelopement To Revenue 3.21  3.05 
Capex To Revenue 0.04  0.03 
Revenue Per Share 0.81  0.85 
Ebit Per Revenue(3.16)(3.32)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GOOGAlphabet Inc Class C
CRMSalesforce

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY